Tenax CEO buys 10,850 shares around $1.85
TENAX THERAPEUTICS, INC.’s CEO bought 10,850 TENX common shares in mid-September 2026 and continues to hold several sizeable stock option awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
TENAX THERAPEUTICS, INC. (TENX) reports that CEO and director Christopher Thomas Giordano purchased a total of 10,850 shares of common stock in two transactions on September 11 and September 15, 2026, at weighted average prices of about $1.88 and $1.82 per share. No Rule 10b5-1 trading plan is reported, and the filing also lists multiple existing stock option awards over several years with vesting schedules tied to continued employment.
Insider Trade Summary
Net Buyer: 10,850 shares
Net Buy
2 txns
Insider
Giordano Christopher Thomas
Role
CEO
Bought
10,850 shs ($20K)
Increase in Position
95.8%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F2 | 4,850 | $1.8221 | $9K |
| Purchase | Common Stock F1 | 6,000 | $1.875 | $11K |
| Holding | Stock Option (right to buy) F3 | -- | -- | -- |
| Holding | Stock Option (right to buy) F4 | -- | -- | -- |
| Holding | Stock Option (right to buy) F5 | -- | -- | -- |
| Holding | Stock Option (right to buy) | -- | -- | -- |
| Holding | Stock Option (right to buy) F6 | -- | -- | -- |
| Holding | Stock Option (right to buy) F7 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 22,174 shares (Direct);
Stock Option (right to buy) — 3,092,000 contracts (Direct)
Holdings Before and After:
Common Stock, 11,324 to 22,174 shares (Direct)
Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (7)
- F1. This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2. This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F3. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
- F4. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
- F5. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
- F6. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
- F7. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
Key Figures
Common shares purchased September 11, 2026: 6,000 shares
Weighted average purchase price September 11, 2026: $1.875 per share
Common shares purchased September 15, 2026: 4,850 shares
+4 more
7 metrics
Common shares purchased September 11, 2026
6,000 shares
Direct purchase of TENAX THERAPEUTICS, INC. common stock by CEO
Weighted average purchase price September 11, 2026
$1.875 per share
Trades executed between $1.87 and $1.88
Common shares purchased September 15, 2026
4,850 shares
Direct purchase of TENAX THERAPEUTICS, INC. common stock by CEO
Weighted average purchase price September 15, 2026
$1.8221 per share
Trades executed between $1.82 and $1.83
Option position expiring January 9, 2036
450,000 underlying shares at $13.30
Stock option on TENAX THERAPEUTICS, INC. common stock held directly
Option position expiring May 16, 2035
1,400,000 underlying shares at $5.89
Stock option on TENAX THERAPEUTICS, INC. common stock held directly
Option position expiring December 10, 2034
1,241,500 underlying shares at $5.94
Stock option on TENAX THERAPEUTICS, INC. common stock held directly
Key Terms
weighted average price, underlying shares of common stock, vest and become exercisable
3 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vest and become exercisable financial
"The options vest and become exercisable as follows: 25% of the underlying shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did TENX CEO Christopher Giordano report in this Form 4?
He reported two purchases of TENAX THERAPEUTICS, INC. common stock, totaling 10,850 shares, on September 11, 2026 and September 15, 2026. Both were acquisitions of shares directly in his name, increasing his reported common stock position.
Were the September 2026 TENX insider purchases made under a Rule 10b5-1 plan?
No. The filing indicates that no Rule 10b5-1 trading plan applies to these transactions, meaning they are not identified as trades executed under a pre-arranged trading plan.
What stock option positions for the TENX CEO are disclosed in this Form 4?
The filing lists several stock option awards on TENAX THERAPEUTICS, INC. common stock, including options with exercise prices of $13.30 on 450,000 underlying shares expiring January 9, 2036, and $5.89 on 1,400,000 underlying shares expiring May 16, 2035, all held directly.
How do the TENX CEO’s stock options vest according to this disclosure?
For example, options on 450,000 underlying shares vest with 25% on January 9, 2027, then 1/36 of the remaining shares vest monthly over 36 months. Similar time-based vesting applies to other awards, all subject to continued employment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
